TMPRSS2-ERG Fusion Heterogeneity in Multifocal Prostate Cancer: Clinical and Biologic Implications - 09/08/11
Reprint requests: Mark A. Rubin, M.D., Weill Cornell Medical College, 1300 York Avenue, Room C 410-A, New York, NY.Résumé |
Objectives |
To characterize the clonality of TMPRSS2-ERG fusion in multifocal prostate cancer.
Methods |
From 80 consecutive radical prostatectomy specimens, we identified 32 cases with multiple spatially separate tumors. In each case, we assessed two to three tumor foci for TMPRSS2-ERG fusion using an ERG break-apart interphase fluorescence in situ hybridization assay.
Results |
Individual tumor foci showed homogeneity for fusion status (intrafocal clonal homogeneity). In 19 (59%) of the 32 cases, all foci within a case had the same fusion status (interfocal homogeneity). In 15 (80%) of the 19 cases, no foci had fusion, and in 4 (20%), all foci had fusion. Of the 32 cases, 13 (41%) demonstrated heterogeneity for fusion status within a case (interfocal clonal heterogeneity).
Conclusions |
In this study, we have demonstrated interfocal heterogeneity and intrafocal homogeneity for TMPRSS2-ERG fusion in prostate cancer with multiple tumors. These findings support the multiclonal nature of prostate cancer with clinical implications for needle biopsy strategies and the development of urine-based screening tests.
Le texte complet de cet article est disponible en PDF.Plan
| This study was supported by the National Institutes of Health Prostate SPORE at the Dana-Farber/Harvard Cancer Center National Cancer Institute grants P50 CA090381 (M. A. Rubin) and R01AG21404 (M. A. Rubin), German Research Foundation DFG grant PE1179/1-2 (S. Perner), and Department of Defense Prostate Cancer Training Award PC061474 (S.P.), and the Prostate Cancer Foundation (F. Demichelis). The University of Michigan and Brigham and Women’s Hospital have a patent for Gene Fusion; and M. A. Rubin, S. Perner, and F. Demichelis are all co-inventors. Supported by the NIH Prostate SPORE at the Dana-Farber/Harvard Cancer Center NCI P50 CA090381 (M.A.R.), R01AG21404 (M.A.R.), German Research Foundation DFG# PE1179/1-2 (S.P.) and Department of Defense Prostate Cancer Training Award PC061474 (S.P.), and the Prostate Cancer Foundation (F.D.). The University of Michigan and the Brigham and Women’s Hospital have a patent for Gene Fusion. Drs. Rubin, Perner and Demichelis are all co-inventors. |
Vol 70 - N° 4
P. 630-633 - octobre 2007 Retour au numéro
Article précédent
- Conservative Management of Renal Trauma: A Review
- Joshua A. Broghammer, Mark B. Fisher, Richard A. Santucci
- Urinary Citrate Levels Do Not Correlate with Urinary pH in Patients with Urinary Stone Formation
- Jared M. Whitson, Matthew R. Cooperberg, G. Bennett Stackhouse, Marshall L. Stoller
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?